Posts

Tariffs on Pharmaceuticals: Are Drug Prices Set to Rise?

Access To The New Alzheimer's Drugs: Why HTA Bodies Are Saying No

Taking on the access hurdles for orphan drugs: preparing for EU HTA

Disrupting HTA and HEOR: the role of AI

Finding new treatments for ALS patients: a look at the late-stage pipeline

EU HTA is now live: what do we do now?

Turning Setbacks into Strategies: Lessons from RELYVIRO’s journey in ALS

Medicamentos modificadores de la enfermedad para el Parkinson: ¿una nueva ola en el horizonte?